Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TVRD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| STAT3 Inhibitor C-188-9 | Hepatocellular Carcinoma | Phase 1/2 · NCT05440708 | Recruiting |
| Aromatase Inhibitor | Breast Cancer | Phase 1 · NCT05384119 | Terminated |
| Control | Squamous Cell Carcinoma of Head and Neck | Early Phase 1 · NCT05845307 | Withdrawn |
Also used in these trials (approved or third-party drugs, not TVRD's own candidates): Atezolizumab, Bevacizumab, Pembrolizumab, Fulvestrant, Palbociclib, Ribociclib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TVRD holds $15.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.5M/quarter from operations, an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 84 · High
Management has determined that its present capital resources as of June 30, 2026 will not be sufficient to fund its planned operations for at least one year from the issuance date of the unaudited condensed consolidated financial statements, included elsewhere in this Quarterly Report, which raises substantial doubt…10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TVRD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Shaheen Wirk Director · +14,011 options |
Insider | 439,194 | 3.29% | 2025-04-15 |
| Samuel David Tweardy 10% owner |
Insider | 315,658 | 2.37% | 2025-07-07 |
| Wallace L Jr Hall Director · +18,000 options |
Insider | 246,756 | 1.85% | 2025-04-15 |
Share count 13,338,943 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVRD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →